News Emergent BioSolutions Inc.

Equities

EBS

US29089Q1058

Market Closed - Nyse Other stock markets 04:00:02 2024-04-15 pm EDT			5-day change	1st Jan Change
1.98 ^USD	-3.88%		-14.66%	-17.50%

Mar. 25	Emergent Gets FDA's 'No Action Indicated' Status For Baltimore Bayview Manufacturing Facility	MT
Mar. 25	Emergent Biosolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Emergent BioSolutions Continues to Broaden Access, Awareness and Availability of NARCAN® Nasal Spray to Help Save Lives from the Ongoing Opioid Crisis	Mar. 28	GL
Emergent Gets FDA's 'No Action Indicated' Status For Baltimore Bayview Manufacturing Facility	Mar. 25	MT
Emergent BioSolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility	Mar. 25	GL
Emergent Biosolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility	Mar. 25	CI
Sector Update: Health Care Stocks Rise Late Afternoon	Mar. 12	MT
Sector Update: Health Care Stocks Higher in Afternoon Trading	Mar. 12	MT
Emergent BioSolutions Tumbles After S&P Global Credit Downgrade	Mar. 12	MT
Emergent BioSolutions Shares Drop on S&P Downgrade	Mar. 12	DJ
North American Morning Briefing : Stock Futures -2-	Mar. 08	DJ
Benchmark Upgrades Emergent Biosolutions to Buy From Hold, Price Target is $5	Mar. 07	MT
News Highlights : Top Company News of the Day - Thursday at 1 AM ET	Mar. 07	DJ
News Highlights : Top Company News of the Day - Wednesday at 11 PM ET	Mar. 06	DJ
News Highlights : Top Company News of the Day - Wednesday at 9 PM ET	Mar. 06	DJ
News Highlights : Top Company News of the Day - Wednesday at 7 PM ET	Mar. 06	DJ
Emergent Biosolutions: Q4 Earnings Snapshot	Mar. 06	AQ
Transcript : Emergent BioSolutions Inc., Q4 2023 Earnings Call, Mar 06, 2024	Mar. 06
(EBS) EMERGENT BIOSOLUTIONS Sees Q1 Revenue Range $200M - $250M	Mar. 06	MT
Earnings Flash (EBS) EMERGENT BIOSOLUTIONS Reports Q4 Revenue $277M, vs. Street Est of $274M	Mar. 06	MT
Emergent BioSolutions Reports Fourth Quarter 2023 Financial Results	Mar. 06	GL
Emergent BioSolutions Inc. Provides Revenue Guidance for the First Quarter and Earnings Guidance for the Full Year of 2024	Mar. 06	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Emergent BioSolutions Inc.

Equities

EBS

US29089Q1058

Summary

Filters